Donna L White1, Yanhong Liu2, Jose Garcia3, Hashem B El-Serag4, Li Jiao5, Spiridon Tsavachidis2, Luis M Franco6, Ju-Seog Lee7, Shahriar Tavakoli-Tabasi8, David Moore9, Radoslav Goldman10, Jill Kuzniarek11, David J Ramsey11, Fasiha Kanwal4, Marco Marcelli12. 1. Clinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuESt), Michael E. DeBakey VA Medical Center and Baylor College of Medicine Houston, TX, USA ; Texas Medical Center Digestive Disease Center Houston, TX, USA ; Dan L. Duncan Cancer Center at Baylor College of Medicine Houston, TX, USA ; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center Houston, TX, USA. 2. Dan L. Duncan Cancer Center at Baylor College of Medicine Houston, TX, USA ; Department of Pediatrics, Baylor College of Medicine Houston, TX, USA. 3. Dan L. Duncan Cancer Center at Baylor College of Medicine Houston, TX, USA ; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center Houston, TX, USA ; Section of Endocrinology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine Houston, TX, USA. 4. Section of Gastroenterology and Hepatology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine Houston, TX, USA ; Clinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuESt), Michael E. DeBakey VA Medical Center and Baylor College of Medicine Houston, TX, USA ; Texas Medical Center Digestive Disease Center Houston, TX, USA ; Dan L. Duncan Cancer Center at Baylor College of Medicine Houston, TX, USA. 5. Section of Gastroenterology and Hepatology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine Houston, TX, USA ; Clinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuESt), Michael E. DeBakey VA Medical Center and Baylor College of Medicine Houston, TX, USA ; Texas Medical Center Digestive Disease Center Houston, TX, USA ; Dan L. Duncan Cancer Center at Baylor College of Medicine Houston, TX, USA ; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center Houston, TX, USA. 6. Department of Molecular and Human Genetics, Baylor College of Medicine Houston, TX, USA. 7. Department of Systems Biology, MD Anderson Cancer Center Houston, TX, USA. 8. Section of Infectious Diseases, Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine Houston, TX, USA. 9. Department Molecular and Cell Biology and Department of Medicine, Baylor College of Medicine Houston, TX, USA. 10. Department of Oncology, Georgetown University Medical Center Washington, DC, USA. 11. Clinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuESt), Michael E. DeBakey VA Medical Center and Baylor College of Medicine Houston, TX, USA. 12. Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center Houston, TX, USA ; Section of Endocrinology, Michael E. DeBakey VA Medical Center and Baylor College of Medicine Houston, TX, USA.
Abstract
BACKGROUND: Males have excess advanced liver disease and cirrhosis risk including from chronic hepatitis C virus (HCV) infection though the reasons are unclear. GOAL: To examine the role variants in genes involved in androgen and estrogen biosynthesis and metabolism play in HCV-related liver disease risk in males. METHODS: We performed a cross-sectional study evaluating single nucleotide polymorphisms (SNPs) in 16 candidate genes involved in androgen and estrogen ligand and receptor synthesis and risk of advanced hepatic fibrosis (F3/F4-F4) and inflammation (A2/A3-A3). We calculated adjusted odds ratios (ORs) using logistic regression and used multifactor dimensionality reduction (MDR) analysis to assess for gene-environment interaction. RESULTS: Among 466 chronically HCV-infected males, 59% (n = 274) had advanced fibrosis and 54% (n = 252) had advanced inflammation. Nine of 472 SNPs were significantly associated with fibrosis risk; 4 in AKR1C3 (e.g., AKR1C3 rs2186174: ORadj = 2.04, 95% CI 1.38-3.02), 1 each in AKR1C2 and ESR1, and 1 in HSD17B6. Four SNPs were associated with inflammation risk, 2 in SRD5A1 (e.g., SRD5A1 rs248800: ORadj = 1.86, 95% CI 1.20-2.88) and 1 each in AKR1C2 and AKR1C3. MDR analysis identified a single AKR1C3 locus (rs2186174) as the best model for advanced fibrosis; while a 4-locus model with diabetes, AKR1C2 rs12414884, SRD5A1 rs6555406, and SRD5A1 rs248800 was best for inflammation. CONCLUSIONS: The consistency of our findings suggests AKR1C isoenzymes 2 and 3, and potentially SRD5A1, may play a role in progression of HCV-related liver disease in males. Future studies are needed to validate these findings and to assess if similar associations exist in females.
BACKGROUND: Males have excess advanced liver disease and cirrhosis risk including from chronic hepatitis C virus (HCV) infection though the reasons are unclear. GOAL: To examine the role variants in genes involved in androgen and estrogen biosynthesis and metabolism play in HCV-related liver disease risk in males. METHODS: We performed a cross-sectional study evaluating single nucleotide polymorphisms (SNPs) in 16 candidate genes involved in androgen and estrogen ligand and receptor synthesis and risk of advanced hepatic fibrosis (F3/F4-F4) and inflammation (A2/A3-A3). We calculated adjusted odds ratios (ORs) using logistic regression and used multifactor dimensionality reduction (MDR) analysis to assess for gene-environment interaction. RESULTS: Among 466 chronically HCV-infected males, 59% (n = 274) had advanced fibrosis and 54% (n = 252) had advanced inflammation. Nine of 472 SNPs were significantly associated with fibrosis risk; 4 in AKR1C3 (e.g., AKR1C3rs2186174: ORadj = 2.04, 95% CI 1.38-3.02), 1 each in AKR1C2 and ESR1, and 1 in HSD17B6. Four SNPs were associated with inflammation risk, 2 in SRD5A1 (e.g., SRD5A1rs248800: ORadj = 1.86, 95% CI 1.20-2.88) and 1 each in AKR1C2 and AKR1C3. MDR analysis identified a single AKR1C3 locus (rs2186174) as the best model for advanced fibrosis; while a 4-locus model with diabetes, AKR1C2rs12414884, SRD5A1rs6555406, and SRD5A1rs248800 was best for inflammation. CONCLUSIONS: The consistency of our findings suggests AKR1C isoenzymes 2 and 3, and potentially SRD5A1, may play a role in progression of HCV-related liver disease in males. Future studies are needed to validate these findings and to assess if similar associations exist in females.
Authors: Muralimohan Yepuru; Zhongzhi Wu; Anand Kulkarni; Feng Yin; Christina M Barrett; Juhyun Kim; Mitchell S Steiner; Duane D Miller; James T Dalton; Ramesh Narayanan Journal: Clin Cancer Res Date: 2013-08-30 Impact factor: 12.531
Authors: Erika M Kwon; Sarah K Holt; Rong Fu; Suzanne Kolb; Gabrielle Williams; Janet L Stanford; Elaine A Ostrander Journal: Cancer Epidemiol Date: 2012-04-26 Impact factor: 2.984
Authors: K Patel; Y Benhamou; E M Yoshida; K D Kaita; S Zeuzem; M Torbenson; E Pulkstenis; G M Subramanian; J G McHutchison Journal: J Viral Hepat Date: 2008-10-24 Impact factor: 3.728
Authors: Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk Journal: Cancer Res Date: 2006-03-01 Impact factor: 12.701
Authors: Andy J Liedtke; Adegoke O Adeniji; Mo Chen; Michael C Byrns; Yi Jin; David W Christianson; Lawrence J Marnett; Trevor M Penning Journal: J Med Chem Date: 2013-03-13 Impact factor: 7.446
Authors: Francesca Pastore; Antonio Martocchia; Manuela Stefanelli; Pietro Prunas; Stefania Giordano; Lavinia Toussan; Antonio Devito; Paolo Falaschi Journal: World J Hepatol Date: 2016-01-18